Drug maker Amgen won an appeals court ruling Monday that prevents an Israeli company from seeking royalties on rheumatoid arthritis treatment Enbrel. Israel Bio-Engineering Project sued Thousand Oaks-based Amgen on charges the company violated Enbrel’s patent. But the L.A. U.S. District Court upheld a ruling that Yeda Research and Development Co., which licenses inventions of the Weizmann Institute of Science in Israel, owns a portion of the patent, thereby blocking the Israel Bio-Engineering Project suit. Enbrel generated $2.88 billion last year in North American sales.
